o	These results indicate that EXACT Therapeutics' Acoustic Cluster Therapy
(ACT®) significantly enhances the local effect of chemotherapy

o	In the patients who had a response to chemotherapy, ACT-treated tumours showed
a significantly greater reduction in diameter compared to control tumours (-29%
vs. -7%, p<0.05)
 
o	Final analysis mirrors the excellent safety profile of PS101 seen in the
interim read-out and suggests a dose-response relationship

o	The data supports the company's plans for its Phase 2 trial (ENACT) in
patients with locally advanced or borderline resectable pancreatic cancer





Oslo, Norway, 20 May 2025. EXACT Therapeutics (Euronext Growth: EXTX), a
clinical-stage precision medicine company, is pleased to announce the final and
positive data set from its Phase 1 ACTIVATE trial. The trial investigated the
use of EXACT's proprietary Acoustic Cluster Therapy with chemotherapy in
hard-to-treat patients with liver metastases of colorectal origin. These
encouraging clinical data provide proof of principle for the clinical
application of ACT technology and offer strong support for initiating the ENACT
Phase 2 study in pancreatic cancer, a disease with a high unmet medical need.

"I am excited about the data from the ACTIVATE trial, which yet again underscore
the attractive therapeutic proposition from our proprietary ACT technology. The
strength of the response to treatment, the safety profile and its non-invasive
nature points to a unique and highly differentiated therapeutic regimen. We
continue our efforts to bring ACT to cancer patients as fast as possible.
Building on the momentum of the ACTIVATE study, we are excited to be approaching
the first patient dosing in our Phase 2 ENACT trial in locally advanced
pancreatic cancer." said Per Walday, CEO of EXACT Therapeutics. 

The final results affirm the previously reported positive ACTIVATE outcomes and
indicate the significant added efficacy of ACT with chemotherapy compared with
chemotherapy alone. Among patients who responded to chemotherapy, tumor
shrinkage was significantly greater with ACT and chemotherapy compared to
chemotherapy alone in the same individuals (-29% vs. -7%, p<0.05). 

ACT treatment with EXACT's proprietary agent PS101 had a clear dose-response
relationship. Shrinkage of tumour lesions was significantly greater in patients
who received 40 µl/kg PS101 compared with 20 µl/kg PS101. In the group of
patients who showed a response to chemotherapy in the control lesions, 3 out of
4 patients who received 40 µl/kg PS101 showed tumour shrinkage of more than 30%
in diameter. Tumour shrinkage was seen in 6 out of 9 patients who received ACT
with chemotherapy. PS101 was safe and well tolerated when given with
chemotherapy. 

Chief Medical Officer of EXACT Therapeutics, Amir Snapir continued, "Today's
update marks the successful completion of the ACTIVATE trial. The results give
us great confidence in the treatment potential of the ACT technology for
patients with solid tumours." 

EXACT Therapeutics is committed to advancing cancer therapies and sharing its
research findings with the broader scientific community. The company plans to
present the detailed data from the Phase 1 ACTIVATE trial in a future scientific
publication and at a forthcoming medical conference. 

The company wishes to thank the patients, their families and the investigators
for their participation and contribution to the ACTIVATE trial.

About the Phase 1 ACTIVATE trial
 
ACTIVATE is a multi-center, single arm, open-label Phase 1 trial to assess the
safety and tolerability, pharmacokinetics, and preliminary anti-cancer activity
of ACT treatment with the chemotherapy regimens FOLFOX or FOLFIRI in patients
with liver metastases of colorectal origin. The trial is designed in the way
that each patient serves as their own control, with primary assessment of
anti-tumour activity consisting of within-patient comparison of radiographic
responses between ACT-treated lesions (insonated plus chemotherapy) and control
lesions (chemotherapy alone, non-insonated). Assessment was done at week 8 by
blinded central review. The trial enrolled 11 hard-to-treat patients, hereof 9
evaluable, at sites in the United Kingdom. Additional information about the
ACTIVATE trial is available at clinicaltrials.gov (NCT04021277).

About Acoustic Cluster Therapy

Acoustic Cluster Therapy (ACT®) consists of PS101 administered intravenously and
insonated over a target tissue with ultrasound. PS101 is a formulation of
microclusters of perfluorobutane microbubbles and perfluoromethylcyclopentane
microdroplets. High frequency insonation causes PS101 to form larger ACT bubbles
that are temporarily lodged in capillaries, followed by low frequency
insonation, which induces oscillation of the lodged ACT bubbles, enhancing the
delivery of the concurrently given chemotherapy to the target tissues. 

About EXACT Therapeutics

EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications, including brain diseases. EXACT Therapeutics'
shares are traded on Euronext Growth Oslo (EXTX). Further information may be
found here:        www.exact-tx.com   

For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com

Forward looking statements:
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement